calithera
biosciences
initiates
keapsake
randomized
phase
trial
telaglenastat
combination
chemoimmunotherapy
treat
aggressive
form
lung
cancer
study
evaluate
safety
efficacy
glutaminase
inhibition
combination
treatment
setting
among
patients
cell
lung
cancer
mutation
pathway
south
san
francisco
globe
newswire
calithera
biosciences
nasdaq
cala
biotechnology
company
focused
discovering
developing
novel
drugs
treatment
cancer
diseases
today
announced
treatment
first
patient
randomized
phase
cell
lung
cancer
nsclc
clinical
trial
glutaminase
inhibitor
telaglenastat
combination
pembrolizumab
carboplatin
pemetrexed
keapsake
study
evaluate
safety
activity
telaglenastat
plus
immunotherapy
therapy
among
patients
stage
iv
nsclc
whose
tumors
mutation
determined
sequencing
mutations
pathway
occur
estimated
percent
nsclc
patients
associated
aggressive
tumor
growth
recently
presented
clinical
data
demonstrate
activation
pathway
either
loss
function
activation
associated
poor
clinical
outcomes
among
patients
nsclc
receiving
chemoimmunotherapy
models
shown
activation
pathway
results
dependence
glutaminase
activity
growth
survival
making
tumors
exquisitely
sensitive
inhibition
glutaminase
activity
telaglenastat
therapies
inhibit
glutaminase
tumors
pathway
activation
could
meaningful
clinical
impact
substantial
percentage
people
nsclc
said
susan
molineaux
phd
president
chief
executive
officer
calithera
proud
keapsake
among
first
clinical
trials
investigating
potential
new
therapy
patients
poor
prognosis
based
clear
mechanistic
rationale
telaglenastat
indication
strong
preclinical
data
hopeful
study
provide
valuable
keapsake
trial
enroll
approximately
patients
stage
iv
nsclc
tumors
mutation
patients
randomized
receive
telaglenastat
placebo
combination
pembrolizumab
carboplatin
pemetrexed
study
evaluate
safety
survival
pfs
telaglenastat
plus
chemoimmunotherapy
regimen
liquid
biopsy
test
provided
study
sponsor
investigational
use
iuo
testing
option
patient
selection
calithera
anticipates
sharing
interim
data
keapsake
trial
telaglenastat
telaglenastat
investigational
novel
glutaminase
inhibitor
specifically
designed
block
cancer
cells
using
glutamine
growth
survival
tumors
commonly
exhibit
metabolic
alterations
increase
dependence
glutamine
preclinical
studies
telaglenastat
produced
synergistic
antitumor
effects
used
combination
therapies
calithera
evaluating
telaglenastat
combination
therapy
approaches
multiple
solid
tumor
types
including
metastatic
renal
cell
carcinoma
cell
lung
cancer
lung
cancer
lung
cancer
one
common
cancers
approximately
new
cases
deaths
projected
according
american
cancer
society
cell
lung
cancer
nsclc
common
type
lung
cancer
accounting
percent
lung
cancer
diagnoses
recently
published
observational
study
demonstrated
survival
patients
genomic
alterations
treated
care
statistically
significantly
shorter
compared
patients
without
mutations
months
months
calithera
calithera
biosciences
biopharmaceutical
company
pioneering
discovery
development
targeted
therapies
disrupt
cellular
metabolic
pathways
preferentially
block
tumor
cells
enhance
activity
driven
commitment
rigorous
science
passion
improving
lives
people
impacted
cancer
diseases
calithera
advancing
pipeline
oral
therapeutics
meaningfully
expand
treatment
options
available
patients
calithera
headquartered
south
san
francisco
california
information
calithera
please
visit
forward
looking
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
anticipate
estimate
intend
poised
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
include
related
safety
tolerability
efficacy
calithera
product
candidates
overall
advancement
calithera
product
candidates
clinical
trials
including
randomized
phase
clinical
trial
telaglenastat
combination
pembrolizumab
carboplatin
pemetrexed
unmet
need
treatment
patients
advanced
disease
calithera
plans
continue
development
product
candidates
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
product
candidates
calithera
develops
may
progress
clinical
development
receive
required
regulatory
approvals
within
expected
timelines
addition
clinical
trials
may
confirm
safety
potency
product
characteristics
described
assumed
press
release
product
candidates
may
beneficial
patients
successfully
commercialized
failure
meet
expectations
respect
foregoing
matters
may
negative
effect
calithera
stock
price
additional
information
concerning
risk
factors
affecting
calithera
business
found
calithera
recent
quarterly
report
form
filed
securities
exchange
commission
periodic
filings
securities
exchange
commission
statements
guarantees
future
performance
speak
date
hereof
except
required
law
calithera
disclaims
obligation
update
statements
reflect
future
events
circumstances
source
calithera
biosciences
inc
contacts
investor
relations
jennifer
mcnealey
calithera
ir
media
michele
parisi
sam
brown
micheleparisi
skoulidis
asco
